Seven oncology approvals included nods for subcutaneous Rybrevant and Lunsumio.
ApexOnco Front Page
Recent articles
The company hands its PD-L1 x VEGF bispecific back to ImmuneOnco.
Duality takes its Adam9-targeting conjugate into the clinic.
It’s a new term for biotech and its investors.
Pumitamig is the latest to be tested in first-line disease.
Qilu moves its GPRC5D T-cell engager into phase 3, but trispecifics set the new pace.
China's Harmoni-A trial hits on overall survival, but hopes for a global phase 3 seem optimistic.
New draft guidance could see the agency getting ever stricter.
